ATE464905T1 - Phosphattransporthemmer - Google Patents

Phosphattransporthemmer

Info

Publication number
ATE464905T1
ATE464905T1 AT06077276T AT06077276T ATE464905T1 AT E464905 T1 ATE464905 T1 AT E464905T1 AT 06077276 T AT06077276 T AT 06077276T AT 06077276 T AT06077276 T AT 06077276T AT E464905 T1 ATE464905 T1 AT E464905T1
Authority
AT
Austria
Prior art keywords
phosphate transport
transport inhibitors
lower alkyl
substituted
alkyl group
Prior art date
Application number
AT06077276T
Other languages
English (en)
Inventor
Stephen Randall Holmes-Farley
Cecilia M Bastos
Andrew T Papoulis
Thomas H Jozefiak
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE464905T1 publication Critical patent/ATE464905T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06077276T 2001-12-26 2002-12-24 Phosphattransporthemmer ATE464905T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34466001P 2001-12-26 2001-12-26
US37164902P 2002-04-10 2002-04-10

Publications (1)

Publication Number Publication Date
ATE464905T1 true ATE464905T1 (de) 2010-05-15

Family

ID=26994039

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02806234T ATE362360T1 (de) 2001-12-26 2002-12-24 Hemmer des phosphattransports
AT06077276T ATE464905T1 (de) 2001-12-26 2002-12-24 Phosphattransporthemmer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02806234T ATE362360T1 (de) 2001-12-26 2002-12-24 Hemmer des phosphattransports

Country Status (7)

Country Link
US (2) US7119120B2 (de)
EP (2) EP1465638B1 (de)
JP (2) JP4610900B2 (de)
AT (2) ATE362360T1 (de)
AU (1) AU2002367396A1 (de)
DE (2) DE60236117D1 (de)
WO (1) WO2003057225A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
CN100497302C (zh) * 2002-09-05 2009-06-10 神经研究公司 二芳基脲衍生物和它们作为氯通道阻滞剂的用途
EP1398029A1 (de) * 2002-09-10 2004-03-17 LION Bioscience AG 3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden
US7491718B2 (en) * 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
WO2004037274A1 (en) * 2002-10-22 2004-05-06 Genzyme Corporation Amine polymers for promoting bone formation
DE10257357A1 (de) * 2002-12-09 2004-06-24 Bayer Ag Fluorhaltige Benzaldehyde
EP1753421B1 (de) * 2004-04-20 2012-08-01 Amgen Inc. Arylsulfonamide und ihre verwendung als hydroxysteroid-dehydrogenase
JP2008516971A (ja) * 2004-10-15 2008-05-22 アルテアーナノ，インコーポレーテッド 錠剤による負荷が軽減されるリン酸塩結合剤
WO2006077901A1 (ja) * 2005-01-20 2006-07-27 Shionogi & Co., Ltd. Ctgf発現阻害剤
JP2009504781A (ja) * 2005-08-17 2009-02-05 アルテアナノ インコーポレイテッド 家畜における高リン血症：治療のための組成物、及び治療方法
AU2006279343A1 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
DE102005044156A1 (de) * 2005-09-15 2007-03-29 Riemser Arzneimittel Ag Substituierte Acetophenonderivate
GB0526255D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526252D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2043627A2 (de) * 2006-07-05 2009-04-08 Genzyme Corporation Eisen(ii)-haltige behandlungen für hyperphosphatämie
CA2685962A1 (en) * 2007-05-08 2009-02-05 Burnham Institute For Medical Research Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
JP2011523655A (ja) * 2008-06-03 2011-08-18 フレセニウス メディカル ケア ドイッチュランド ゲーエムベーハー ガンマセクレターゼモジュレータを含む医薬組成物
EP2687513B1 (de) * 2008-06-09 2020-12-02 Ludwig-Maximilians-Universität München Medikamente zur hemmung der aggregation von proteinen bei krankheiten, die mit proteinaggregation und/oder neurodegenerativen erkrankungen in zusammenhang stehen
CA2729767A1 (en) * 2008-07-07 2010-01-14 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX381407B (es) 2008-12-31 2025-03-12 Ardelyx Inc Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
ES2633689T3 (es) 2009-01-26 2017-09-22 Opko Ireland Global Holdings, Limited Regulación de fosfato con moléculas pequeñas
MX337575B (es) 2009-10-09 2016-03-10 Zafgen Corp Compuestos de sulfona y métodos para lafabricación y uso de éstos.
AU2011222551B2 (en) * 2010-03-05 2016-10-06 Duophos Arylfluorophosphate inhibitors of intestinal apical membrane sodium/phosphate co-transport
ES2871021T3 (es) 2010-05-12 2021-10-28 Spectrum Pharmaceuticals Inc Hidróxido de carbonato de lantano, oxicarbonato de lantano y procedimientos de fabricación y uso
WO2012006473A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012054110A2 (en) 2010-07-07 2012-04-26 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827328B2 (ja) * 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
WO2012006474A2 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
AU2011281037B2 (en) 2010-07-22 2014-11-27 Zafgen, Inc. Tricyclic compounds and methods of making and using same
WO2012103333A1 (en) 2011-01-26 2012-08-02 Zafgen Corporation Tetrazole compounds and methods of making and using same
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
SG194812A1 (en) 2011-05-06 2013-12-30 Zafgen Inc Partially saturated tricyclic compounds and methods of making and using same
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
WO2013109735A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX2015005733A (es) 2012-11-05 2016-02-10 Zafgen Inc Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
KR20150079952A (ko) 2012-11-05 2015-07-08 자프겐 인크. 트리시클릭 화합물 및 그의 제조 및 사용 방법
BR112015010196A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc métodos de tratar doença do fígado
HRP20191000T1 (hr) 2013-04-12 2019-09-20 Ardelyx, Inc. Spojevi za vezanje nhe3 i metode inhibiranja transporta fosfata
CN103467452B (zh) * 2013-09-11 2015-11-18 陕西理工学院 一种苯甲酰胺类化合物及其应用
CN106008360B (zh) * 2016-08-11 2018-10-16 华南农业大学 一种对氨基苯磺酰咪唑及其制备方法
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
JP7120549B2 (ja) * 2016-12-15 2022-08-17 小野薬品工業株式会社 Ｔｒｅｋ（ｔｗｉｋ関連ｋチャネル）チャネルのアクチベータ
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.
MX395405B (es) 2017-01-09 2025-03-25 Ardelyx Inc Compuestos útiles para tratar trastornos del tracto gastrointestinal.
WO2019028343A1 (en) * 2017-08-03 2019-02-07 Georgetown University SMALL MOLECULE INHIBITORS OF SLC25A1
EP4324329A3 (de) * 2018-01-17 2024-04-17 Migal Galilee Research Institute Ltd. Neue methionin-stoffwechselweghemmer
EP3740482A1 (de) 2018-01-17 2020-11-25 Migal Galilee Research Institute Ltd. Neue inhibitoren des methionin-stoffwechselweges
CN110305045A (zh) * 2018-03-20 2019-10-08 成都海创药业有限公司 一种酰胺类化合物及其在治疗癌症中的用途
EP4140991B1 (de) * 2018-06-01 2024-05-15 Promega Corporation Biolumineszenz-komplexe aus oplophorus-luciferase-hemmern
EP3927702A4 (de) 2019-04-11 2022-05-11 Angion Biomedica Corp. Feste formen von (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazol
WO2021041561A2 (en) * 2019-08-26 2021-03-04 Avantaggiati Mauria Laura Treating non-alcoholic fatty liver disease and inflammatory steatohepatitis with slc25a1 inhibitors
CN119212723A (zh) * 2022-05-11 2024-12-27 中外制药株式会社 用于治疗或预防囊性疾病的药物组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ14795A3 (en) 1992-07-28 1996-07-17 Rhone Poulenc Rorer Ltd Benzene derivative containing phenyl group bound to aryl or heteroaryl fraction through an aliphatic or hetero atom containing group, process of its preparation and pharmaceutical composition containing thereof
EP0619116A3 (en) 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5716993A (en) * 1993-12-27 1998-02-10 Eisai Co., Ltd. Anthranilic acid derivatives
KR19990067010A (ko) 1995-10-23 1999-08-16 오스테오스크린, 인코포레이티드 골결핍 상태의 치료용 조성물 및 그 치료방법
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
WO1999007382A1 (en) 1997-08-06 1999-02-18 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
JP3972163B2 (ja) * 1999-06-18 2007-09-05 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
AR030911A1 (es) 1999-07-20 2003-09-03 Smithkline Beecham Corp Uso de n-aril-2-sulfonamidobenzamidas para la manufactura de un medicamento para el tratamiento de la insuficiencia renal cronica y composiciones farmaceuticas
WO2001082924A1 (en) 2000-05-02 2001-11-08 Smithkline Beecham Corporation Phosphate transport inhibitors
IL152587A0 (en) 2000-05-12 2003-05-29 Smithkline Beecham Corp Phosphate transport inhibitors
AU2002213048A1 (en) * 2000-10-05 2002-04-15 Smith Kline Beecham Corporation Phosphate transport inhibitors
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors

Also Published As

Publication number Publication date
JP2010132674A (ja) 2010-06-17
EP1815860A2 (de) 2007-08-08
ATE362360T1 (de) 2007-06-15
US20040019113A1 (en) 2004-01-29
EP1815860B1 (de) 2010-04-21
EP1465638B1 (de) 2007-05-16
US7119120B2 (en) 2006-10-10
DE60220188T2 (de) 2008-01-24
AU2002367396A1 (en) 2003-07-24
DE60236117D1 (de) 2010-06-02
JP4610900B2 (ja) 2011-01-12
WO2003057225A2 (en) 2003-07-17
DE60220188D1 (de) 2007-06-28
EP1815860A3 (de) 2007-11-21
EP1465638A2 (de) 2004-10-13
US20070021509A1 (en) 2007-01-25
JP2005514413A (ja) 2005-05-19
WO2003057225A3 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
ATE464905T1 (de) Phosphattransporthemmer
DK0931788T3 (da) Metalloproteasehæmmere
DE69221794D1 (de) 3-benzyliden-1-carbamoyl-2-pyrrolidon-analoga
ES2059408T3 (es) Un proceso para la preparacion de un compuesto.
EA200000048A1 (ru) ИНГИБИТОРЫ ФАКТОРА Ха, СОДЕРЖАЩИЕ ГРУППУ С НЕЙТРАЛЬНОЙ P1-СПЕЦИФИЧНОСТЬЮ
EA199900591A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха
IT1290823B1 (it) Idrossifeniltriazine
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
EA200400361A1 (ru) Производные алкинарилнафтиридин-4(1h)-онов в качестве ингибитора фосфодиэстеразы типа iv
PT1250340E (pt) Metodos e compostos para inibicao de mrp1
ATE384722T1 (de) Alkoxypyridinderivate
DK0618193T3 (da) Nitrogenholdige, bicycliske derivater som prolyl-endopeptidaseinhibitorer
DE60111228D1 (de) Heteropolycyclische inhibitoren
DK1000034T3 (da) Substituerede 6-alkylphenanthridiner
GB2178959B (en) Biocidal mixture
BR0311223A (pt) Método para o uso de derivados de piranindol para tratar infecção pelo vìrus da hepatite c
EA200101230A1 (ru) Новые ингибиторы металлопротеаз, метод их получения и содержащие их фармацевтические композиции
DK0668279T3 (da) 6-azaindol thromboxansytaseinhibitor
DK0844241T3 (da) Inhibitor af narkotisk analgetisk afhængighed/resistensudvikling
ATE430476T1 (de) Schlammbehandlung
AR247750A1 (es) Sistema inhibidor de polimerizacion y composicion estabilizada que lo comprende.
MXPA04002039A (es) Mezclas fungicidas.
DK0777471T3 (da) Inhibering af leukotrienbiosynese med urinstofderivater
MXPA03005556A (es) Derivados de 1,1-dioxo-1,2-benzotiacina-3-carboxamidas, metodo para prepararlos y composiciones farmaceuticas que los contienen.
DE60108873D1 (de) Nicht-antibakterielle tetrazykline als anti-pilz medikamente

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties